NEW YORK, Jan. 9, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.Today we are offering reports on EDIT, ILMN, TSRO, and ECYT which can be accessed for free by signing up to www.wallstequities.com/registration. On Monday, January 08, 2018, the NASDAQ Composite ended the trading session
Cambridge, Massachusetts-based Editas Medicine Inc.'s stock finished Monday's session 10.63% lower at $30.02 with a total trading volume of 6.03 million shares, which was above its three months average volume of 1.11 million shares. The Company's shares have advanced 19.25% in the last month, 20.03% in the previous three months, and 71.44% over the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 14.45% and 42.82%, respectively. Additionally, shares of Editas Medicine, which operates as a genome editing company, have a Relative Strength Index (RSI) of 55.05. Get the full research report on EDIT for free by clicking below at: www.wallstequities.com/registration/?symbol=EDIT
On Monday, shares in San Diego, California headquartered Illumina Inc. recorded a trading volume of 956,244 shares, which was above its three months average volume of 768.58 thousand shares. The stock ended the session 0.49% lower at $227.06. The Company's shares have advanced 11.21% in the previous three months and 60.48% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 5.74% and 17.33%, respectively. Moreover, shares of Illumina, which provides sequencing and array-based solutions for genetic analysis, have an RSI of 60.48.
On January 05th, 2018, research firm BTIG Research initiated a 'Neutral' rating on the Company's stock. Get access to our top-rated research, including the free report on ILMN at: www.wallstequities.com/registration/?symbol=ILMN
Waltham, Massachusetts headquartered Tesaro Inc.'s shares closed the day 3.84% lower at $75.28. The stock recorded a trading volume of 931,456 shares, which was above its three months average volume of 864.09 thousand shares. The stock is trading below its 50-day moving average by 15.66%. Additionally, shares of Tesaro, which identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the US, have an RSI of 33.47.
On December 20th, 2017, research firm Citigroup reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $216 a share to $135 a share. Click here to subscribe for a free membership which welcomes you with our report on TSRO at: www.wallstequities.com/registration/?symbol=TSRO
Shares in West Lafayette, Indiana headquartered Endocyte Inc. finished 3.23% lower at $4.20. The stock recorded a trading volume of 462,759 shares. The Company's shares have advanced 57.30% over the last twelve months. The stock is trading above its 200-day moving average by 50.70%. Furthermore, shares of Endocyte, which develops targeted therapies for the treatment of cancer and inflammatory diseases in the US, have an RSI of 41.78. Join our big investor community at Wall St. Equities today and get your free report on ECYT at: www.wallstequities.com/registration/?symbol=ECYT
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: firstname.lastname@example.orgPhone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/stock-review-for-biotechs-investors----editas-medicine-illumina-tesaro-and-endocyte-300579757.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Abortion pills are used in the first trimester to terminate pregnancy. Women should be aware of ...
Tea tree oil is an essential oil derived from the leaves of the Melaleuca alternifolia plant and ...
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...View All